Showing Results for: “Glycemic Index and Diabetes”

Yesterday, Maryland Governor Lawrence (Larry) Hogan, Jr. signed Senate Bill 353 and House Bill 1397 – a critical action that will help save lives and reduce the burden of insulin costs for people living with diabetes in Maryland. The American Diabetes Association® (ADA) applauds Governor Hogan for signing the legislation that will cap copayments for insulin at $30 per 30-day supply for those on state-regulated commercial health insurance plans. Improving insulin affordability helps people with diabetes to manage the disease, stay healthy, and reduce their risk for dangerous complications

In a victory for children with disabilities, a federal court ruled today that the City of New York’s Department of Education (“DOE”) routinely denies students with diabetes access to field trips and bus transportation in violation of the Americans with Disabilities Act (“ADA”), Section 504 of the Rehabilitation Act (“Section 504”), and the New York City Human Rights Law (“NYCHRL”). Plaintiffs in this lawsuit are the American Diabetes Association ® (“Association”), the nation’s leading diabetes organization, and three individual students with diabetes who attend New York City schools. Click

Last week, at its first-ever Cost of Care Summit, the American Diabetes Association ® (ADA) shared the results of a new study on Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race . The study, featuring analysis by Health Management Associates, finds that although access to CGMs provides potentially life-changing benefits for diabetes management, poorer, older, and Black Americans have less access to these devices than others. “It is disappointing to see that, today, access to vital diabetes management technology like CGMs is uneven and

Update on SCORED and SOLOIST trials shows reduction in cardiovascular events and stroke using glucose-lowering agents Results from two large clinical trials show significant and early benefits from sotagliflozin, a drug that inhibits sodium-glucose transport protein 2 (SGLT2) and sodium-glucose transport protein 1 (SGLT1) in reducing heart failure, heart attack, and stroke—major problems in people with diabetes. The findings were presented at the virtual 81st Scientific Sessions of the American Diabetes Association ® (ADA). Patients with diabetes are at an increased risk of life-threatening

Leading diabetes researchers and clinicians from around the world highlight impact of health disparities on diabetes care The American Diabetes Association® (ADA) is highlighting the latest understanding of how to address health disparities laid bare by the pandemic at the virtual 81st Scientific Sessions. Taking place June 25–29, the ADA’s Scientific Sessions is the world’s largest scientific meeting focused on diabetes research, prevention, and care. These expert discussions come at a time when 76% of Americans currently living in poverty are people of color. Diabetes prevalence is inversely

A new consensus report addressing the benefits, challenges, and recommendations related to automated insulin delivery (AID) is being jointly published today by two leading diabetes organizations: the American Diabetes Association ® (ADA) and the European Association for the Study of Diabetes (EASD). The ADA and the EASD convened a joint Diabetes Technology Working Group to review the current landscape of AID systems and recommend targeted actions. “The report addresses the clinical usage of AID systems from a practical point of view rather than as a meta-analysis or a review of all relevant

The American Diabetes Association ® (ADA) has launched new requests for applications (RFAs) for the Fall 2022 Grant Cycle to research and expand the field of knowledge to improve the lives of those living with diabetes. The critical topics for research include supporting the behavioral and mental health of people with diabetes, tackling the epidemic of youth onset type 2 diabetes, and improving the lives of women living with diabetes. Each topic offers multiple award mechanisms including—postdoctoral fellowships, junior faculty development, innovative basic, and innovative clinical or

Tracey D. Brown, Chief Executive Officer of the American Diabetes Association (ADA), issued the following statement in response to the unprecedented number of Members of Congress who invited people living with diabetes to join them at President Donald J. Trump’s State of the Union address: “Tonight, at least 13 Members of Congress will host their constituents that are living with diabetes, and who represent the seven million Americans dependent on insulin, at the State of the Union address. They will elevate the voices of all people with diabetes and their families, many of whom struggle to

Results of the PIONEER 6 trial indicate oral semaglutide is safe for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk, according to results announced at the symposium titled “Oral Semaglutide—The PIONEER Program Trials” today at the American Diabetes Association’s® (ADA) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. Oral semaglutide reduced cardiovascular death and all-cause mortality by nearly 50 percent, based on median follow up of 15.9 months. PIONEER 6 was conducted across 21 countries and included 3,183 participants who were randomized

Frank J. Snoek, PhD, has been selected to receive the American Diabetes Association's® (ADA's) 2019 Richard R. Rubin Award. This award recognizes a behavioral researcher who has made outstanding, innovative contributions to the study and understanding of the behavioral aspects of diabetes in diverse populations. Dr. Snoek will be recognized with this honor during the ADA’s 79th Scientific Sessions, June 7–11, 2019, at the Moscone Convention Center in San Francisco. He will deliver the Richard R. Rubin Award Lecture titled, “ #DiabetesPsychologyMatters ,” on Saturday, June 8. Currently, Dr